BIIB · Biogen Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Capital expenditures | 41M | Q2 2026 | — |
| EMPAVELI revenue | 46M | Q2 2026 | — |
| Free cash flow non-GAAP | 408M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by (used in) operating activities 448.9M
-40.9M Purchases of property, plant and equipment
= Free cash flow 408M
|
|||
| Growth Portfolio revenue | 1.06B | Q2 2026 | — |
| Legacy MS Portfolio revenue | 767M | Q2 2026 | — |
| LEQEMBI global in-market sales | 184M | Q2 2026 | — |
|
|
|||
| LEQEMBI U.S. in-market sales | 97M | Q2 2026 | — |
|
|
|||
| Net cash flow from operations | 449M | Q2 2026 | — |
| SKYCLARYS revenue | 168M | Q2 2026 | — |
| SPINRAZA revenue | 402M | Q2 2026 | — |
| SYFOVRE revenue | 162M | Q2 2026 | — |
| VUMERITY revenue | 197M | Q2 2026 | — |
| Weighted average diluted shares | 149M | Q2 2026 | — |
| ZURZUVAE revenue | 71M | Q2 2026 | — |
|
|
|||
| QALSODY global revenue | 33M | Q1 2026 | — |
| SKYCLARYS global revenue | 151M | Q1 2026 | — |
| SPINRAZA global revenue | 374M | Q1 2026 | — |
| VUMERITY global revenue | 179M | Q1 2026 | — |
| Full year 2025 revenue from growth products year-over-year change | 19% | FY 2025 | — |
| LEQEMBI fourth quarter global in-market sales | 134M | Q4 2025 | — |
| LEQEMBI fourth quarter U.S. in-market sales | 78M | Q4 2025 | — |
| SKYCLARYS fourth quarter ex-U.S. revenue | 44M | Q4 2025 | — |
| SKYCLARYS fourth quarter U.S. revenue | 89M | Q4 2025 | — |
| SPINRAZA fourth quarter year-over-year revenue change | -15% | Q4 2025 | — |
| VUMERITY fourth quarter year-over-year revenue growth | 3% | Q4 2025 | — |
| ZURZUVAE fourth quarter revenue | 66M | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIIB
this stock
Biogen Inc.
|
$30.98B | +19.2% | +2.2% | — | 3.7% |
|
LLY
ELI LILLY & Co
|
$1.11T | +9.8% | +44.7% | 39.6 | 1.0% |
|
JNJ
Johnson & Johnson
|
$627.42B | +25.8% | +6.0% | 30.2 | 1.1% |
|
ABBV
AbbVie Inc.
|
$440.83B | +9.2% | +8.6% | 70.5 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$335.14B | +29.1% | +1.3% | 108.7 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIIB | +0.9% | +1.9% | +6.9% | +3.4% | +19.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.5% | -2.6% | -6.9% | -0.5% | +5.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.